Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

543
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
543
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.5K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

395
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
395
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

591
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591
Angina IV: Management01:26

Angina IV: Management

408
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
408

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing mortality, improving outcomes, and establishing equity for women with classical haematological disease: a Lancet Haematology Commission.

The Lancet. Haematology·2026
Same author

Should we focus on sustainable thromboprophylaxis and avoid overuse of low-molecular-weight heparins?

Research and practice in thrombosis and haemostasis·2026
Same author

Renal Vein Thrombosis: A Narrative Review.

Diagnostics (Basel, Switzerland)·2026
Same author

DIC in pregnancy: lessons from an international registry of the International Society for Thrombosis and Hemostasis: Communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Coagulopathy in acute promyelocytic leukaemia: Can we better predict and prevent catastrophic bleeding?

Thrombosis research·2026
Same author

Where Is the 'Oma' in Multiple Myeloma? Origins and Limitations of some Myeloma-Related Terminology.

EJHaem·2026

Related Experiment Video

Updated: Mar 23, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.4K

Antiplatelet therapy - a summary for the general physicians.

Jecko Thachil1

  • 1Department of Haematology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. jecko.thachil@cmft.nhs.uk.

Clinical Medicine (London, England)
|April 3, 2016
PubMed
Summary

Antiplatelet therapies are crucial for preventing recurrent arterial ischaemic events. Newer agents like prasugrel and ticagrelor offer potent options beyond aspirin and clopidogrel, expanding treatment possibilities.

Keywords:
Plateletsantiplatelet aspirinclopidogrelplateletsprasugrelticagrelor

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K

Related Experiment Videos

Last Updated: Mar 23, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.4K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K

Area of Science:

  • Cardiovascular Medicine
  • Hematology

Background:

  • Platelets are vital for hemostasis and thrombosis.
  • Platelet aggregation drives arterial ischemic events like stroke and heart attack.
  • Antiplatelet therapy is essential for secondary prevention in affected individuals.

Purpose of the Study:

  • To review available antiplatelet agents.
  • To discuss practical considerations for general physicians.
  • To highlight the evolving landscape of antiplatelet therapy.

Main Methods:

  • Literature review of antiplatelet agents.
  • Discussion of clinical applications and emerging therapies.
  • Focus on general physician's perspective.

Main Results:

  • The antiplatelet therapy landscape has evolved significantly.
  • Aspirin and clopidogrel were traditional agents.
  • Newer potent agents include prasugrel, ticagrelor, and glycoprotein IIb/IIIa antagonists.
  • Emerging therapies include protease-activated receptor-1 antagonists and cangrelor.

Conclusions:

  • The range of antiplatelet drugs has expanded considerably.
  • Understanding these agents is crucial for managing arterial ischemic events.
  • Practical guidance for general physicians is provided.